Finally, with the aim of enhancing generation of cytotoxic T cells by stimulating intra-tumoural dendritic cell (DC) activation, NCT03435640 is testing the combination of bemppegaldesleukin with NKTR-262, a small molecule TLR7/8 agonist designed to activate antigen-presenting cells (APCs) in the tumour microenvironment, with the bempegaldesleukin/NKTR-262 dual combination being compared to a triplet combination with Nivolumab. Here, NKTR is linked to neoplasm.